News
Convalescent Plasma Not Efficacious in Hospitalized COVID-19 Patients
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
Your search for supplemental oxygen returned 19 results
News
Asian, Black, Hispanic Patients Have Higher Pulse Oximetry Readings
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
News
Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
News
Dapagliflozin Does Not Improve Kidney Outcomes in Hospitalized COVID-19 Cases
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Drugs in the Pipeline
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Drugs in the Pipeline
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
News
Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Drugs in the Pipeline
Baricitinib Alone Authorized for COVID-19 Under Revised EUA
The update was based on data from the COV-BARRIER study.
News
FDA Authorizes Emergency Use of Actemra for COVID-19
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Drugs in the Pipeline
Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
